Physician profile
Gary Daniel
NPI 1447218862
$28,327.17
in general payments reported to CMS, 2019-2025
30 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $256 · 2021: $534 · 2022: $1,643 · 2023: $24K · 2024: $1,355 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $24K · Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $23,500.00 |
| Food and Beverage | $2,061.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $24,422.24 | 2022-2025 | Auryon Laser System 100-120 Vac, Alphavac |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $659.96 | 2020-2024 | Lifevest |
| Boston Scientific Corporation | $586.18 | 2019-2025 | Watchman Flx, Bodyguardian, Jetstream Sc |
| Endologix LLC | $438.95 | 2022-2024 | Endocross Device, Torus Stent Graft System |
| Abbott Laboratories | $277.62 | 2020-2024 | Xience Skypoint, Perclose Prostyle, Herculink Elite |
| Abiomed | $251.47 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $197.39 | 2021-2025 | |
| Pfizer INC. | $153.69 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $149.60 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.52 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $145.53 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $138.74 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $108.87 | 2019-2022 | |
| Inari Medical, INC. | $96.92 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $91.49 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $88.27 | 2019-2022 | |
| Medtronic, INC. | $72.49 | 2021-2023 | Abre |
| Merck Sharp & Dohme LLC | $49.23 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $40.27 | 2019-2023 | |
| Novo Nordisk INC | $37.14 | 2021 | |
| Bard Peripheral Vascular, INC. | $34.51 | 2020 | |
| Daiichi Sankyo INC. | $27.51 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $18.82 | 2024 | |
| Medtronic Vascular, INC. | $15.98 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.50 | 2021 | |
| Cordis US Corp. | $13.79 | 2023 | Rain Sheath Transradial |
| Esperion Therapeutics, INC. | $13.20 | 2024 | Nexletol |
| Medline Industries Lp | $13.01 | 2022 | |
| G Medical Diagnostic Services, INC. | $11.77 | 2022 | |
| Cvrx, INC. | $11.51 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.